

Eye Cancer: Front to Back Care

Saturday, March 21, 2026

8:00 am Welcome and Opening Remarks

Robert S. Feder, MD

Session 1: Ocular Surface

8:10 am Can imiquimod be used for OSSN and MIS?

Chris Bowen, MD, MS

8:30 am A Masquerade Ball

Robert S. Feder, MD

8:45 am Is corneal transplant possible after plaque?

Ramez I. Haddadin, MD

9:00 am How to manage conjunctival melanoma with positive margins?

Chris Bowen, MD, MS

9:15 am What are the take home pearls for ocular pathology?

Paul J. Bryar, MD

9:25 am Panel Discussion – Q&A

Moderators: *Ramez I. Haddadin, MD & Chris Bowen, MD, MS*

9:30 am Break

Session 2: Uveal Melanoma and Retinoblastoma

9:35 am How is 3D plaque planning performed?

Timothy Sita, MD, PhD

9:50 am How is proton planning created?

Amanda McDermott, MS, CMD R.T.

10:05 am What is the DRCR AL clinical trial?

Kevin X. Zhang, MD

10:20 am How does MYC-C gene change management?

Janice Lasky Zeid, MD

10:35 am What are uveal melanoma mimickers?

Sayed Saeed Mohammadi, MD

10:50 am Panel Discussion – Q&A

Moderators: *Alice T. Lyon, MD & Chris Bowen, MD, MS*

10:55 am Break

Session 3: Ocular Lymphoma

11:05 am Radiation: A cure for glaucoma?

Dalia V. Zhang, MD

11:20 am Vitreoretinal lymphoma or something else?

Timothy M. Janetos, MD, MBA

11:35 am Can liquid biopsy monitor vitreoretinal lymphoma?

Chris Bowen, MD, MS

11:50 am Emerging treatments for PCNSL: What is best?

Karan S. Dixit, MD

12:05 pm Panel Discussion – Q&A

Moderators: *Karan S. Dixit, MD & Chris Bowen, MD, MS*

12:10 pm Break

Session 4: Emerging Innovations in Ophthalmology

12:20 pm Telemedicine in Ophthalmology: is this possible?

Carol L. Shields, MD

12:40 pm Panel Discussion – Q&A

Moderators: *Carol L. Shields, MD & Chris Bowen, MD, MS*

12:50 pm Closing Comments and Adjournment

Chris Bowen, MD, MS